Affymax (AFFY) Prices 4.1M Shares at $18.25/Share
More News related to AFFY
- Affymax to Present at the 12th Annual BIO CEO & Investor Conference
- Affymax (AFFY) Completes Hematide Phase 3
- Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide(TM), to Treat Anemia in Chronic Renal Failure
- BioCentury Publishes BioTech Picks for FY10 (HGSI, VRTX, AMGN, More...)
- BioCentury Publishes Investor Picks for New Biotech Bellwethers in 2010
More News related to Equity Offerings
- Hoku Scientific (HOKU) Files 20.01M Common Shelf for a Selling Shareholder
- China Agritech (CAGC) Files $100M Mixed Securities Shelf
- ChinaTel Group (CHTL) Jumps Higher On 'Above-Market' Equity Financing
- Developers Diversified Realty (DDR) Prices 37.3M Common Offering at $8.16/Share
- EV Energy Partners (EVEP) Prices 3M Common Unit Offering at $28.08/Unit
Affymax, Inc. (Nasdaq: AFFY) today announced that it has priced an underwritten public offering of 4,109,589 shares of its common stock at a price of $18.25 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $69.6 million. Affymax has granted the underwriters a thirty-day option to purchase up to 616,438 additional shares of common stock to cover overallotments, if any. The offering is expected to close on or about November 24, 2009, subject to satisfaction of customary closing conditions.
Cowen and Company, LLC and Lazard Capital Markets LLC are acting as joint book-runners, with RBC Capital Markets Corporation and Robert W. Baird & Co. Incorporated acting as co-managers for the offering.
Related Categories
Equity OfferingsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
